GLSI News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GL

Mkt Cap

$213.0M

Volume

101.83K

Next Earnings

November 13th

Loading chart

GL

GLSIGreenwich LifeSciences, Inc.

GLSI

Pay with—

Available Balance0.00

GL

Mkt Cap

$224.9M

Volume

101.83K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

Greenwich LifeSciences Provides Update Regarding Form 10-K FilingGreenwich LifeSciences reported delays in filing its Form 10-K for fiscal year 2025 due to coordination issues between dual auditors regarding accounts payable adjustments related to its Phase III FLAMINGO-01 clinical trial. The company maintains a cash balance of approximately $10.5 million as of March 31, 2026, and reported preliminary positive data from the trial showing a 70-80% reduction in breast cancer recurrence rates in the non-HLA-A*02 patient arm.GlobeNewswire Inc. · Jun 1, 2026

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026Greenwich LifeSciences announced that an abstract presenting preliminary data from its Phase III FLAMINGO-01 trial of GLSI-100 immunotherapy has been accepted for presentation at the 2026 ASCO Annual Meeting (May 28-June 2). The non-HLA-A*02 open-label arm, now fully enrolled with 250 patients, shows approximately 70-80% reduction in breast cancer recurrence rates after the Primary Immunization Series, consistent with Phase IIb results. The company plans to attend multiple oncology conferences in coming months.GlobeNewswire Inc. · Apr 23, 2026

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingGreenwich LifeSciences received a notification from Nasdaq on April 16, 2026, indicating non-compliance with listing rules due to failure to timely file its Annual Report on Form 10-K for fiscal year 2025. The company's stock continues to trade on Nasdaq Capital Market under ticker GLSI with no immediate effect on listing status. The company is working with auditors to file the report as soon as possible.GlobeNewswire Inc. · Apr 22, 2026

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026Greenwich LifeSciences presented preliminary immune response data from the Phase III FLAMINGO-01 trial of GLSI-100, an immunotherapy for breast cancer recurrence prevention. The non-HLA-A*02 open label arm (247 patients) showed a statistically significant 4-fold increase in delayed-type-hypersensitivity (DTH) immune reactions from 5.2% at baseline to 20.4% at months 4-6 (p<0.001). Preliminary recurrence rate analysis showed approximately 70-80% reduction in recurrence rates after the primary immunization series, supporting the drug's mechanism of action. Over 1,300 patients have been screened for the trial to date.GlobeNewswire Inc. · Apr 20, 2026

Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market PotentialGreenwich LifeSciences announced new patent claims for GLSI-100 based on Phase III FLAMINGO-01 trial data showing statistically significant immune response and approximately 80% recurrence rate reduction in non-HLA-A*02 breast cancer patients. The claims potentially double the addressable market by an additional 100% (88,000 new patients annually in US and Europe) and could provide patent protection through 2045. The company has begun enrolling both HLA-A*02 and non-HLA-A*02 patients in the same randomized arms following FDA approval of protocol changes.GlobeNewswire Inc. · Apr 7, 2026

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01Greenwich LifeSciences announced the activation of new FLAMINGO-01 Phase III clinical trial sites at City of Hope across multiple U.S. locations, with renowned breast cancer expert Dr. Hope Rugo joining as principal investigator. The trial evaluating GLSI-100 immunotherapy for breast cancer recurrence prevention has expanded from 160 to potentially 190-200 sites, with preliminary data from the non-HLA-A*02 arm showing approximately 70-80% reduction in recurrence rates, consistent with Phase IIb results.GlobeNewswire Inc. · Mar 19, 2026

Greenwich LifeSciences Provides Update on Upcoming AACR MeetingGreenwich LifeSciences announced that two abstracts and two posters were accepted for presentation at the AACR Meeting 2026. The company reported preliminary data from the open-label arm of FLAMINGO-01 Phase III trial showing statistically significant immune response results for GLSI-100, an immunotherapy designed to prevent breast cancer recurrences. The non-HLA-A*02 arm showed approximately 70-80% reduction in recurrence rates after the Primary Immunization Series, consistent with Phase IIb trial results.GlobeNewswire Inc. · Mar 18, 2026

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01Greenwich LifeSciences announced that all 40 US sites in its Phase III FLAMINGO-01 trial are now treating patients with commercially manufactured GP2 vials following FDA approval. The company is expanding manufacturing capacity to 500,000-1 million vials annually and plans to submit manufacturing data to European, UK, and Canadian regulators. Preliminary data from the non-HLA-A*02 arm shows approximately 80% reduction in breast cancer recurrence rates, consistent with Phase IIb results.GlobeNewswire Inc. · Mar 16, 2026

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01Greenwich LifeSciences announced a significant 33% increase in patient screening rates for its Phase III FLAMINGO-01 trial, reaching over 800 patients per year. The non-HLA-A*02 arm is fully enrolled with 250 patients, showing preliminary recurrence rate reductions of approximately 80%, consistent with Phase IIb results. The company continues expanding clinical sites globally.GlobeNewswire Inc. · Mar 3, 2026

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026Greenwich LifeSciences announced that two abstracts have been accepted for presentation at the AACR Annual Meeting 2026 (April 17-22), including the first abstract co-authored with the full FLAMINGO-01 Steering Committee. The Phase III trial's non-HLA-A*02 arm is fully enrolled with 250 patients, showing preliminary results of approximately 80% reduction in recurrence rates after the Primary Immunization Series, consistent with Phase IIb trial outcomes.GlobeNewswire Inc. · Feb 24, 2026

to start trading

GL

GLSIGreenwich LifeSciences, Inc.

GLSI

Pay with—

Available Balance0.00

Your PositionYou don't own any GLSI yet.

Related Tickers

Earnings